Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy

Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institute of Health, 9 Memorial Drive, Bethesda, MD 20892, USA.
Current drug targets (Impact Factor: 3.02). 08/2010; 11(8):1000-17. DOI: 10.2174/138945010791591395
Source: PubMed

ABSTRACT

New blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) signaling pathway plays pivotal roles in regulating tumor angiogenesis. VEGF as a therapeutic target has been validated in various types of human cancers. Different agents including antibodies, aptamers, peptides, and small molecules have been extensively investigated to block VEGF and its pro-angiogenic functions. Some of these agents have been approved by FDA and some are currently in clinical trials. Combination therapies are also being pursued for better tumor control. By providing comprehensive real-time information, molecular imaging of VEGF pathway may accelerate the drug development process. Moreover, the imaging will be of great help for patient stratification and therapeutic effect monitoring, which will promote effective personalized molecular cancer therapy. This review summarizes the current status of tumor therapeutic agents targeting to VEGF and the applications of VEGF related molecular imaging.

Download full-text

Full-text

Available from: Gang Niu, Sep 03, 2015
  • Source
    • "Vascular endothelial growth factor (VEGF) is a signal protein that stimulates vasculogenesis and angiogenesis. VEGF belongs to a sub-family of growth factors, specifically the platelet-derived growth factor family of cystine-knot growth factors (Niu and Chen, 2010). Overexpression of VEGF has been associated with tumor progression and poor prognosis in cancer (Hicklin and Ellis, 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The association between vascular endothelial growth factor (VEGF) gene polymorphisms and risk of cancer has been investigated in several studies published previously; however, the individual results are inconclusive. Therefore, we performed a meta-analysis to establish evidence for an association between the VEGF -634 G/C polymorphism and risk of cancer. We searched PubMed, Medline, and Korean Studies Information Service System databases and identified 29 case-control studies, containing data of 25,324 individuals, for this meta-analysis. The odds ratio (OR) and 95% confidence interval (95%CI) were used to determine the strength of the association. Overall, no significant association was detected in the allele model (G allele vs C allele, OR = 0.98, 95%CI = 0.93-1.03), dominant model (G/G+G/C vs C/C, OR = 1.00, 95%CI = 0.90-1.11), or recessive model (G/G vs G/C+C/C, OR = 0.96, 95%CI = 0.89-1.03). The meta-analysis results suggest that the VEGF -634 G/C polymorphism may not be related to the development of cancer. However, additional studies with larger sample size are required in order to provide supporting evidence.
    Preview · Article · Nov 2015 · Genetics and molecular research: GMR
  • Source
    • "The National Institutes of Health (NIH) website provides a basic summary of anti-angiogenic drugs that were or are still currently under clinical investigations (http://www.cancer.gov/clinicaltrials/developments/antiangio-table). These include monoclonal antibodies targeting VEGF ligands or VEGFRs [14], soluble receptors that sequester ligands [15] and small molecule inhibitors that inhibit kinase activity [16]. Three drugs developed for their anti-angiogenic actions, bevacizumab (Avastin®), sunitinib malate (Sutent®, SU11248) and sorafenib (Nexavar®, BAY 43-9006), have been approved by the United States Food and Drug Administration for treatment of patients with specific types of cancer—all three inhibit VEGF signaling by blocking VEGF ligand or VEGFR [17]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anti-angiogenesis targeting VEGFR2 has been considered as an important strategy for cancer therapy. Tylophorine is known to possess anti-inflammatory and antitumor activity, but its roles in tumor angiogenesis, the key step involved in tumor growth and metastasis, and the involved molecular mechanism is still unknown. Therefore, we examined its anti-angiogenic effects and mechanisms in vitro and in vivo. We used tylophorine and analyzed its inhibitory effects on human umbilical vein endothelial cells (HUVEC) in vitro and Ehrlich ascites carcinoma (EAC) tumor in vivo. Tylophorine significantly inhibited a series of VEGF-induced angiogenesis processes including proliferation, migration, and tube formation of endothelial cells. Besides, it directly inhibited VEGFR2 tyrosine kinase activity and its downstream signaling pathways including Akt, Erk and ROS in endothelial cells. Using HUVECs we demonstrated that tylophorine inhibited VEGF-stimulated inflammatory responses including IL-6, IL-8, TNF-alpha, IFN-gamma, MMP-2 and NO secretion. Tylophorine significantly inhibited neovascularization in sponge implant angiogenesis assay and also inhibited tumor angiogenesis and tumor growth in vivo. Molecular docking simulation indicated that tylophorine could form hydrogen bonds and aromatic interactions within the ATP-binding region of the VEGFR2 kinase unit. Tylophorine exerts anti-angiogenesis effects via VEGFR2 signaling pathway thus, may be a viable drug candidate in anti-angiogenesis and anti-cancer therapies.
    Full-text · Article · Jul 2013 · Molecular Cancer
  • [Show abstract] [Hide abstract]
    ABSTRACT: The author describes the KSR 1 system software and its role in bringing the benefits of programmability and scalability to the user. The system software consists of KSR OS, a UNIX compatible operating system, the preprocessors and compilers that comprise the language system, and the parallel programming tools that provide analysis and synthesis support to the parallel programmer
    No preview · Conference Paper · Mar 1993
Show more